- Published on
Medicine – Anogenital Warts: Human Papillomavirus (HPV), Clinical Features, Diagnosis, Treatment and Prevention
1. Introduction to Anogenital Warts
Anogenital warts are common sexually transmitted lesions caused by infection with certain types of human papillomavirus (HPV). They are also known as condylomata acuminata and typically appear as benign epithelial growths involving the genital and perianal regions.
The lesions may develop on the penis, glans penis, vulva, labia, vagina, cervix, perineum, perianal skin or anal canal. They vary considerably in size, number and appearance, ranging from small, flat papules to larger cauliflower-like growths.
Anogenital warts are usually benign and do not directly threaten life. However, they may cause discomfort, itching, bleeding, psychological distress and cosmetic concerns.
An important characteristic of HPV infection is its ability to persist within epithelial tissues, which helps explain why anogenital warts may recur after apparently successful treatment.
2. Aetiology – Human Papillomavirus
Anogenital warts are caused by human papillomavirus, a small, non-enveloped, double-stranded DNA virus belonging to the Papillomaviridae family.
HPV infects squamous epithelial cells of the skin and mucous membranes. It enters through microscopic breaks in the epithelial surface and establishes infection in the basal layer of the epithelium.
The original notes mention approximately 60 HPV types. However, more than 200 HPV types have now been identified, including numerous types capable of infecting the anogenital region.
Different HPV types have different clinical associations. Some predominantly cause benign warts, whereas others are associated with precancerous epithelial abnormalities and invasive malignancy.
3. Classification of HPV into Low-Risk and High-Risk Types
HPV types are commonly classified according to their oncogenic potential.
Low-risk HPV types are primarily associated with benign epithelial proliferations, including anogenital warts. HPV types 6 and 11 are responsible for approximately 90% of anogenital warts.
These types have low oncogenic potential and are not the principal causes of cervical carcinoma.
High-risk HPV types are associated with precancerous lesions and malignancies involving the cervix, anus, penis, vulva, vagina and oropharynx.
HPV types 16 and 18 are particularly important because they account for a large proportion of cervical cancers worldwide.
The essential distinction is that HPV 6 and 11 predominantly cause genital warts, whereas HPV 16 and 18 are strongly associated with cervical cancer.
4. Transmission of HPV Infection
HPV is transmitted primarily through direct skin-to-skin or mucosal contact during sexual activity.
Transmission may occur during vaginal, anal or oral sexual contact, including contact that does not involve penetrative intercourse.
The virus can spread from individuals who have visible anogenital warts as well as those who have no clinically apparent lesions.
Microscopic epithelial injuries facilitate entry of the virus into the basal epithelial layer.
Condoms reduce the risk of HPV transmission but do not provide complete protection because HPV may infect areas of skin not covered by a condom.
HPV infection is extremely common among sexually active individuals, and many infections resolve spontaneously through the host immune response.
5. Incubation Period
The incubation period between HPV acquisition and the development of visible anogenital warts is variable.
Warts may become apparent several weeks or months after infection, although some infections remain clinically silent for prolonged periods.
The development of warts depends on viral replication, host immunity and local epithelial conditions.
Because HPV may persist without symptoms, the appearance of anogenital warts does not reliably indicate when the infection was acquired.
It is therefore usually impossible to determine the exact timing or source of HPV transmission from the appearance of warts alone.
6. Pathogenesis of Anogenital Warts
HPV enters the epithelium through microscopic abrasions and infects basal keratinocytes.
The viral genome persists within infected epithelial cells and uses the host cellular machinery for replication.
As infected cells differentiate and move toward the epithelial surface, viral replication and protein production contribute to epithelial proliferation.
This produces thickening of the epithelium and the formation of papillary or verrucous lesions.
Low-risk HPV types, particularly HPV 6 and 11, stimulate epithelial growth without the strong oncogenic effects associated with high-risk HPV types.
The resulting lesions are typically benign, although they may become extensive or recurrent.
7. Histopathological Features
Anogenital warts are benign squamous epithelial proliferations.
Histologically, they commonly demonstrate acanthosis, papillomatosis and hyperkeratosis or parakeratosis.
A characteristic microscopic feature is koilocytosis.
Koilocytes are squamous epithelial cells showing perinuclear clearing or halos, often accompanied by enlarged, irregular or hyperchromatic nuclei.
These cellular changes reflect the effects of HPV infection on epithelial cells.
Although koilocytosis supports HPV-associated epithelial changes, it does not independently identify the HPV type or establish whether the infection is high-risk.
Clinical Features of Anogenital Warts
8. General Appearance
Anogenital warts may appear as small, flesh-coloured, pink, brown or grey papules.
They may be flat, dome-shaped, papillary or pedunculated.
Some lesions develop a characteristic cauliflower-like appearance, particularly when several warts merge into larger clusters.
The surface may be smooth or irregular.
Warts can occur individually or in groups and may enlarge gradually over time.
The number and size of lesions vary substantially between patients.
9. Genital Warts in Men
In men, anogenital warts commonly develop on the penile shaft, glans penis, coronal sulcus, foreskin and scrotal skin.
They may also occur around the anus or within the anal canal.
Lesions on the glans penis or beneath the foreskin may be particularly noticeable during genital examination.
Most lesions are painless, although friction or local irritation can produce discomfort.
Extensive lesions may interfere with hygiene or sexual activity.
10. Genital Warts in Women
In women, anogenital warts commonly involve the vulva, labia majora, labia minora, vaginal opening, perineum and perianal skin.
They may also develop within the vagina or on the cervix.
External lesions are often visible, whereas internal vaginal or cervical lesions may be detected during pelvic examination.
Patients may experience itching, irritation, local discomfort or occasional bleeding.
Some individuals remain entirely asymptomatic and become aware of the lesions only during routine examination.
11. Perianal and Anal Warts
Perianal warts occur around the external anal opening.
They may appear as small papules or larger clusters of verrucous lesions.
Anal canal warts may occur in individuals with or without a history of receptive anal intercourse.
Symptoms may include itching, irritation, bleeding or discomfort during defecation.
Extensive lesions can occasionally produce difficulties with hygiene or local obstruction.
Patients with suspected intra-anal lesions may require further examination, including anoscopy when appropriate.
12. Symptoms of Anogenital Warts
Most anogenital warts are asymptomatic.
When symptoms occur, they commonly include itching, burning, local irritation and discomfort.
Lesions may bleed after friction, scratching or sexual intercourse.
Large or extensive warts may cause cosmetic concerns and interfere with normal activities.
The psychological effects of anogenital warts can be significant because patients may experience anxiety about transmission, recurrence and possible cancer risk.
However, the presence of typical genital warts does not mean that a patient has cancer.
13. Risk Factors for Anogenital Warts
The risk of acquiring HPV increases with sexual exposure to infected partners.
Having multiple sexual partners or a new sexual partner may increase the probability of exposure.
Immunosuppression is an important risk factor for persistent, extensive or recurrent HPV-associated disease.
Patients with HIV infection or those receiving immunosuppressive medications may develop larger numbers of warts and may respond less well to treatment.
Smoking is also associated with impaired HPV clearance and persistence of infection.
Lack of HPV vaccination increases susceptibility to infection with vaccine-preventable HPV types.
Diagnosis of Anogenital Warts
14. Clinical Diagnosis
Anogenital warts are usually diagnosed through visual inspection of the affected skin and mucous membranes.
Their characteristic papillary or cauliflower-like appearance often makes the diagnosis straightforward.
A clinical examination should assess the number, size, distribution and morphology of lesions.
The examination may include the external genitalia, perineum and perianal region, depending on the patient’s symptoms and presentation.
HPV DNA testing is not routinely recommended for diagnosing visible anogenital warts, because identifying the viral type generally does not change wart management.
15. Indications for Biopsy
Although most anogenital warts can be diagnosed clinically, biopsy may be necessary when the appearance is atypical or the diagnosis is uncertain.
Features that may warrant biopsy include pigmentation, ulceration, induration, fixation to underlying tissues, spontaneous bleeding or unusually rapid growth.
Biopsy may also be considered when lesions fail to respond to standard treatment or worsen during therapy.
This is particularly important in immunocompromised individuals, who may have an increased risk of HPV-associated dysplasia or malignancy.
Histological examination helps distinguish benign warts from premalignant or malignant lesions.
16. Differential Diagnosis
Several conditions can resemble anogenital warts.
Condylomata lata, associated with secondary syphilis, are typically broad, flat, moist lesions and may resemble HPV-associated warts.
Molluscum contagiosum produces small, dome-shaped papules with central umbilication.
Vestibular papillomatosis is a benign anatomical variation of the vulvar vestibule that can resemble small genital warts.
Pearly penile papules are another benign anatomical variant that may be mistaken for HPV infection.
Seborrhoeic keratoses, skin tags and certain premalignant or malignant epithelial lesions may also resemble anogenital warts.
Accurate diagnosis is important because management differs between these conditions.
Treatment of Anogenital Warts
17. Principles of Treatment
Treatment aims to remove visible lesions, relieve symptoms and improve cosmetic appearance.
However, removal of visible warts does not necessarily eradicate HPV from surrounding epithelial tissues.
This explains why recurrence is common after treatment.
Treatment selection depends on the size, number and anatomical location of the lesions, patient preference, pregnancy status and availability of treatment.
Some warts resolve spontaneously without intervention, while others persist or increase in size.
Observation may be appropriate for selected asymptomatic patients.
18. Cryotherapy
Cryotherapy is a commonly used treatment for anogenital warts.
It involves applying liquid nitrogen or another suitable freezing agent to the lesions.
The extreme cold produces tissue injury and destruction of wart-containing epithelial cells.
The treated lesion may subsequently blister, crust and separate from the surrounding tissue.
Cryotherapy can be effective for external genital and perianal warts.
Several treatment sessions may be necessary, particularly when lesions are numerous or extensive.
Adverse effects include pain, blistering, local inflammation and temporary or persistent changes in skin pigmentation.
19. Podophyllin and Podophyllotoxin
The original notes identify podophyllin as a treatment for anogenital warts.
Podophyllin resin is an older preparation containing compounds that interfere with cell division.
However, podophyllin resin is no longer recommended as a preferred treatment in many modern guidelines because its composition is variable and it may cause significant local or systemic toxicity.
Podophyllotoxin, also called podofilox, is a more standardised antimitotic medication used for selected external anogenital warts.
It interferes with microtubule function and inhibits mitosis in infected epithelial cells.
Podophyllotoxin is not suitable for all anatomical sites and must be used according to the prescribed regimen.
Podophyllin and podophyllotoxin should not be used during pregnancy.
20. Imiquimod
Imiquimod is a topical immune-response modifier used for selected external anogenital warts.
It activates local immune pathways, including toll-like receptor 7 signalling, and promotes antiviral immune responses.
Unlike treatments that directly destroy wart tissue, imiquimod enhances the host immune response against HPV-infected cells.
It may be applied by the patient according to an appropriate treatment schedule.
Adverse effects include redness, burning, irritation and local inflammation.
The suitability of imiquimod depends on lesion location and patient circumstances.
21. Trichloroacetic Acid
Trichloroacetic acid is a chemical treatment that destroys wart tissue through protein coagulation.
It is applied directly to the lesion by a trained healthcare professional.
The treatment may be useful for selected small genital or mucosal warts.
Repeated applications may be required.
Care is necessary because contact with surrounding healthy tissue can cause irritation or chemical injury.
Trichloroacetic acid is one of the treatment options that may be used during pregnancy when clinically appropriate.
22. Surgical Removal
Surgical treatment may be considered for large, extensive, persistent or treatment-resistant anogenital warts.
Methods include surgical excision, electrosurgery and laser treatment.
These approaches can remove substantial lesions relatively quickly.
However, they may require local or general anaesthesia, depending on the extent and anatomical location of disease.
Potential complications include pain, bleeding, scarring and infection.
Recurrence remains possible because treatment removes visible lesions without guaranteeing complete viral clearance.
23. Treatment During Pregnancy
Anogenital warts may enlarge or become more numerous during pregnancy because of hormonal and immune changes.
Treatment selection requires particular care because some topical medications are contraindicated.
Podophyllin, podophyllotoxin and sinecatechins should not be used during pregnancy. Imiquimod is generally avoided because pregnancy safety data are limited.
Cryotherapy and clinician-applied trichloroacetic acid are commonly considered when treatment is necessary.
Caesarean delivery is not routinely recommended solely to prevent neonatal HPV transmission.
It may be indicated if extensive warts obstruct the birth canal or create a significant risk of bleeding during vaginal delivery.
Recurrence of Anogenital Warts
24. Why Anogenital Warts Recur
Anogenital warts frequently recur after treatment.
This occurs because HPV may persist within epithelial cells even after visible lesions have been destroyed.
Local treatments primarily remove abnormal tissue rather than eliminating every infected cell.
The host immune response plays an important role in controlling viral persistence.
Recurrence is particularly common during the first few months following treatment.
Immunosuppressed patients may experience more frequent or extensive recurrence.
25. Management of Recurrent Warts
Recurrent anogenital warts may be treated using the same method previously employed or an alternative treatment.
The choice depends on lesion characteristics, previous treatment response and patient preference.
Patients with repeated recurrence may benefit from reassessment of the diagnosis and consideration of underlying immunosuppression.
Atypical or treatment-resistant lesions may require biopsy.
Counselling is important because recurrence does not necessarily indicate recent reinfection or treatment failure.
HPV and Malignancy
26. HPV Types 16 and 18
HPV types 16 and 18 are classified as high-risk oncogenic HPV types.
They are strongly associated with cervical intraepithelial neoplasia and invasive cervical carcinoma.
Persistent infection with high-risk HPV can lead to progressive epithelial abnormalities and, in some patients, malignant transformation.
HPV 16 is particularly important in cervical and other HPV-associated cancers.
HPV 18 is also strongly associated with cervical cancer, including a notable association with cervical adenocarcinoma.
Together, HPV 16 and 18 account for approximately 70% of cervical cancers worldwide.
27. Pathogenesis of HPV-Associated Cancer
High-risk HPV types produce viral proteins that interfere with normal cellular growth regulation.
Two important viral oncoproteins are E6 and E7.
The E6 protein promotes degradation of the tumour suppressor protein p53.
The E7 protein interferes with the retinoblastoma tumour suppressor protein, pRb.
These effects disrupt cell-cycle control and impair normal mechanisms that prevent abnormal cellular proliferation.
Persistent high-risk HPV infection can therefore contribute to dysplasia and eventual malignant transformation.
Cancer development usually requires persistent infection over many years and is not an inevitable consequence of HPV exposure.
28. Cervical Intraepithelial Neoplasia
Cervical intraepithelial neoplasia (CIN) refers to precancerous epithelial abnormalities of the cervix.
It is strongly associated with persistent infection by high-risk HPV types.
CIN is traditionally graded according to the extent of epithelial dysplasia.
CIN 1 represents mild dysplasia and often regresses spontaneously.
CIN 2 and CIN 3 represent higher-grade abnormalities with a greater risk of progression if untreated.
Modern histopathological terminology also uses low-grade and high-grade squamous intraepithelial lesions.
Cervical screening aims to detect high-risk HPV infection and precancerous changes before invasive carcinoma develops.
29. Other HPV-Associated Malignancies
High-risk HPV infection is associated with several malignancies beyond cervical carcinoma.
These include anal squamous cell carcinoma, vulvar carcinoma, vaginal carcinoma and penile carcinoma.
HPV is also associated with a substantial proportion of oropharyngeal squamous cell carcinomas, particularly those involving the tonsils and base of the tongue.
HPV 16 is especially important in many of these cancers.
The risk of malignancy depends on persistent high-risk HPV infection and additional host or environmental factors.
30. Do Genital Warts Cause Cervical Cancer?
Typical anogenital warts are usually caused by low-risk HPV types 6 and 11.
These types are not the principal causes of cervical carcinoma.
Therefore, ordinary genital warts do not usually progress into cervical cancer.
However, an individual may be infected with more than one HPV type simultaneously.
A person with genital warts may also have a separate high-risk HPV infection.
Consequently, the presence or absence of genital warts does not replace the need for appropriate cervical cancer screening.
Prevention of Anogenital Warts
31. HPV Vaccination
HPV vaccination is an important strategy for preventing HPV-associated disease.
Vaccination can reduce the risk of infection with HPV types responsible for genital warts and several HPV-associated cancers.
The nine-valent HPV vaccine provides protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.
HPV types 6 and 11 are associated with most genital warts.
The remaining types included in the nine-valent vaccine are important high-risk oncogenic types.
Vaccination is most effective when administered before exposure to HPV, although it may still provide benefit in eligible individuals who are already sexually active.
32. Limitations of HPV Vaccination
HPV vaccines are preventive rather than therapeutic.
They reduce the risk of future infection with vaccine-covered HPV types but do not eliminate an established HPV infection.
Vaccination does not directly treat existing anogenital warts.
It also does not guarantee protection against every HPV type.
Therefore, vaccination should be combined with appropriate sexual health measures and recommended cervical screening.
33. Cervical Cancer Screening
Cervical cancer screening aims to detect high-risk HPV infection and precancerous cervical abnormalities before invasive cancer develops.
Depending on local guidelines, screening may involve primary HPV testing, cervical cytology or a combination of methods.
Screening recommendations vary according to age, previous results and national healthcare guidance.
Individuals who have received HPV vaccination should still follow applicable cervical screening recommendations.
The absence of genital warts does not exclude high-risk HPV infection.
34. Sexual Health Counselling
Patients with anogenital warts should be informed that HPV is common and may be transmitted even when visible lesions are absent.
Condom use reduces, but does not eliminate, transmission risk.
Avoiding sexual contact while visible warts are present or while treated areas are healing may reduce exposure and local irritation.
Patients should also be offered appropriate assessment for other sexually transmitted infections according to their clinical history and risk factors.
There is no routine recommendation to use HPV testing to determine whether the sexual partner of a person with genital warts has acquired the same infection.
Anogenital Warts and Syphilis – Important Distinction
35. Condylomata Acuminata
Condylomata acuminata are anogenital warts caused predominantly by HPV types 6 and 11.
They typically appear as flesh-coloured, papillary or cauliflower-like lesions.
They are benign epithelial proliferations.
Treatment may involve cryotherapy, topical medications or surgical removal.
36. Condylomata Lata
Condylomata lata are lesions associated with secondary syphilis caused by Treponema pallidum.
They are typically broad, flat, moist plaques that occur in genital or perianal regions.
These lesions contain large numbers of spirochaetes and are highly infectious.
Unlike HPV-associated warts, condylomata lata are treated with systemic penicillin according to the stage of syphilis.
The key distinction is condylomata acuminata = HPV, whereas condylomata lata = secondary syphilis.
Important Corrections to the Original Notes
37. Number of HPV Types
The original notes mention up to 60 different HPV types.
This reflects older classifications.
More than 200 HPV types are now recognised, although not all infect the anogenital region.
38. Benign Nature of Anogenital Warts
The original description of anogenital warts as benign skin tumours is broadly correct.
More precisely, they are benign epithelial proliferations caused by HPV infection.
Typical warts are associated with low-risk HPV types rather than the high-risk types responsible for most cervical cancers.
39. Treatment with Cryotherapy and Podophyllin
Cryotherapy remains an established treatment for anogenital warts.
However, podophyllin resin is an older treatment that is generally not preferred in modern guidelines because of toxicity concerns.
More commonly used treatments include cryotherapy, imiquimod, podophyllotoxin, trichloroacetic acid and surgical removal.
The most appropriate option depends on the location, extent and characteristics of the lesions.
40. Recurrence
The original statement that anogenital warts often recur is correct.
Recurrence occurs because HPV may persist within epithelial cells after visible lesions have been removed.
Treatment reduces or removes visible warts but does not guarantee eradication of the underlying viral infection.
41. Association with Cervical Carcinoma
The original statement that HPV types 16 and 18 are associated with cervical carcinoma is correct.
However, these high-risk types should be distinguished from HPV types 6 and 11, which cause most anogenital warts.
The presence of benign genital warts does not mean that cervical cancer will develop.
Persistent infection with high-risk HPV is the principal concern for HPV-associated malignant transformation.
Important Clinical Associations – Note Form
42. HPV Types 6 and 11
HPV types 6 and 11 are low-risk types responsible for approximately 90% of anogenital warts.
They produce benign epithelial proliferations, commonly presenting as papillary or cauliflower-like lesions.
They are also associated with recurrent respiratory papillomatosis, a condition involving papillomatous growths in the respiratory tract.
43. HPV Types 16 and 18
HPV types 16 and 18 are high-risk oncogenic types strongly associated with cervical carcinoma.
They contribute to malignant transformation through viral proteins that interfere with p53 and retinoblastoma protein function.
Persistent infection is the major risk factor for progression to precancerous lesions and invasive cancer.
44. Cryotherapy
Cryotherapy uses freezing to destroy wart-containing tissue.
It is an established clinician-applied treatment for external anogenital warts.
Several sessions may be necessary, and recurrence remains possible.
45. Podophyllotoxin
Podophyllotoxin is an antimitotic medication used for selected external anogenital warts.
It interferes with microtubule function and inhibits cell division.
It must not be used during pregnancy.
46. Imiquimod
Imiquimod stimulates local immune responses against HPV-infected cells.
It is used for selected external anogenital warts.
Local irritation and inflammation are common adverse effects.
47. HPV Vaccination
HPV vaccination reduces the risk of infection with vaccine-covered HPV types.
The nine-valent vaccine protects against types associated with most genital warts and many HPV-related cancers.
Vaccination is preventive and does not cure established HPV infection.
Key Clinical Pattern
The most important distinction is between low-risk HPV types that cause benign anogenital warts and high-risk HPV types associated with malignant transformation.
HPV 6 and 11 → Low-risk types → Anogenital warts (condylomata acuminata).
HPV 16 and 18 → High-risk types → Cervical carcinoma and other HPV-associated cancers.
Anogenital warts → Flesh-coloured, papillary or cauliflower-like lesions involving the genital or perianal region.
Koilocytosis → Characteristic histological change associated with HPV infection.
Cryotherapy → Freezing and destruction of wart tissue.
Podophyllotoxin → Inhibits mitosis and destroys wart-containing epithelial cells.
Imiquimod → Stimulates local immune responses against HPV-infected cells.
Recurrent warts → Persistence of HPV in epithelial tissue despite removal of visible lesions.
HPV E6 → Promotes degradation of p53.
HPV E7 → Interferes with retinoblastoma protein (pRb).
Condylomata acuminata → HPV infection.
Condylomata lata → Secondary syphilis.
HPV vaccination → Prevention of vaccine-covered HPV infections, genital warts and HPV-associated cancers.
For examinations, remember that HPV types 6 and 11 cause most genital warts, while HPV types 16 and 18 are strongly associated with cervical carcinoma. Anogenital warts are generally diagnosed clinically, treated with local destructive or immune-modifying therapies, and may recur because treatment does not necessarily eliminate persistent HPV infection.